FDA
Clarity Receives U.S. FDA Fast Track Designation for Cu-64 SAR-bisPSMA in Biochemical Recurrence of Prostate Cancer
Clarity
PR-01-25-NI-25Jan 24, 2025
FDA Approves First PSMA-Targeted PET Imaging Drug for Men with Prostate Cancer
U.S. Food & Drug Administration
PR-M11-20-028Dec 02, 2020
Oncology
FDA Will Use Real-Time Oncology Review for Prostate Cancer Drug
Pharma's Almanac
PAO-M05-19-NI-012May 10, 2019
Sun Pharma Announces USFDA Approval of YONSA® (abiraterone acetate) To Treat Metastatic Castration-Resistant Prostate Cancer In Combination With Methylprednisolone
Sun Pharma
PR-M05-18-NI-098May 25, 2018
Clinical Trial
ERLEADA™ Significantly Reduced Risk of Prostate Specific Antigen (PSA) Progression in Patients with Non-Metastatic Castration-Resistant Prostate Cancer
Janssen Pharmaceutical Companies
PR-M05-18-NI-086May 23, 2018